# An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

> **NCT03708965** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **JCR Pharmaceuticals Co., Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Mucopolysaccharidosis II

## Interventions

- **DRUG:** JR-141

## Key facts

- **NCT ID:** NCT03708965
- **Lead sponsor:** JCR Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03708965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03708965, "An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03708965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*